Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Feb 9, 2018 (9 years ago)

Estrone USP for prescription compounding

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Lack of stability data and controls to support the manufacturers assigned retest or expiration date in firm's container/closure system.

Cause type: Stability / shelf life

The product degraded or failed stability testing before its labeled expiry. Heat, moisture or time can break the drug down into degradants or reduce potency. All stability / shelf life recalls.

What was recalled

Estrone USP for prescription compounding, packaged in a) 5 g (NDC 58597-8049-3); b) 100mg (NDC 58597-8049-1); c) 25 g (NDC 58597-8049-4), RX only, packed by American Pharmaceutical Ingredients, LLC 6650 Highland Road, Waterford, MI 48327

Affected NDCs 58597-8049-01 58597-8049-03 58597-8049-04

Compare with the code on your package — it is the most precise check available.

Drug: Estrone

Recalling firm
American Pharmaceutical Ingredients LLC
NDC code
58597-8049-3
Origin
MI, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0491-2018 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Estrone recalls

See all
Class II · Moderate risk

Estrone USP

cGMP Deviations; lack of quality assurance.

Terminated cGMP deviation American Pharmaceutical Ingredients LLC D-0919-2017
Class II · Moderate risk

Estrone

cGMP Deviations: lack of quality assurance at the API manufacturer.

Terminated cGMP deviation Fagron, Inc NDC 51552-0445-2 D-0792-2017
Class II · Moderate risk

Estrone

cGMP Deviations; manufacturer initiated recall of API product after deficiencies noted during a recent FDA inspection

Terminated cGMP deviation Medisca, Inc. NDC 38779-0891-05 D-0664-2017
Class II · Moderate risk

Estrone Micronized

cGMP Deviations; lack of quality assurance.

Terminated cGMP deviation Qinhuangdao Zizhu Pharmaceutical, Co. NDC 44132-003-04 D-0657-2017

Other recalls by American Pharmaceutical Ingredients LLC

All 2018 recalls
Class II · Moderate risk

Sermorelin Acetate

Stability Data Does Not Support Expiry: Stability data from manufacturer does not support expiration dates listed.

Terminated Stability / shelf life American Pharmaceutical Ingredients LLC NDC 58597-8092-1 D-0592-2018
Class II · Moderate risk

Oxytocin USP

Stability Data Does Not Support Expiry: Stability data from manufacturer does not support expiration dates listed.

Terminated Stability / shelf life American Pharmaceutical Ingredients LLC NDC 58597-7042-3 D-0591-2018
Class II · Moderate risk

Fluticasone propionate USP

CGMP Deviations: Lack of stability data and controls to support the manufacturers assigned retest or expiration date in firm's container/closure system.

Terminated Stability / shelf life American Pharmaceutical Ingredients LLC NDC 58597-8276-3 D-0539-2018
Class II · Moderate risk

Cyanocobalamin USP

CGMP Deviations: Lack of stability data and controls to support the manufacturers assigned retest or expiration date in firm's container/closure system.

Terminated Stability / shelf life American Pharmaceutical Ingredients LLC NDC 58597-8044-1 D-0538-2018